Q-omics provides the consensus-scored MAP7D1 profile across patient tissues and cancer cell-line models. MAP7D1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MAP7D1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, MAP7D1 protein abundance shows 24,999 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight MESO, and HNSC as cancer lineages where MAP7D1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP7D1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP7D1 survival associations across molecular data types. MAP7D1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP7D1 RNA expression–survival associations across cancer types. High MAP7D1 expression shows unfavorable associations in MESO, LIHC, LUSC, BLCA and LGG, but favorable associations in ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MAP7D1 RNA expression.
This table summarizes MAP7D1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAP7D1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP7D1 shows lower tumor expression in BLCA and BRCA and higher tumor expression in HNSC, LIHC, KIRC and THCA. The HNSC box plot shows higher MAP7D1 RNA expression in tumor versus normal tissue (log2 FC = +0.922, t-test p < 0.001).
This table shows molecular features associated with MAP7D1 in patient tissues and cancer cell lines. In patient samples, MAP7D1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP7D1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
